Author

S. J. Kerns

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

M. Kanellias· 2 shared A. B. Roth· 1 shared A. Freimoser-Grundschober· 1 shared A. M. Giusti· 1 shared A. Moisan· 1 shared A. P. Simpson· 1 shared A. Schneider· 1 shared C. Belgur· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

M. Kanellias

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phenotypic Characterization of Liver Sinusoidal Endothelial Cells on the Human Liver-Chip for Potential in vitro Therapeutic Antibody Pharmacology Applications

P. L. Candarlioglu, S. Jadalannagari, J. Chaff, J. Velez, S. R. Joshipura, M. Kanellias, A. P. Simpson, S. J. Kerns, L. Ewart, M. Hegde, J. Ekert

This paper describes a Liver-Chip model that maintains CD32B expression on LSECs for 14 days, enabling in vitro studies of therapeutic antibody pharmacology.

bioRxiv · Mar 4, 2022 · PreprintBioengineering

Human immunocompetent Organs-on-Chips platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies

L. Cabon, D. Petropolis, W. Tien-Street, P. R. Ng, H. S. Grant, K. Karalis, G. A. Hamilton, J. Sam, T. Weinzierl, T. Fauti, A. Freimoser-Grundschober, J. Eckmann, C. Hage, M. Geiger, V. Micallef, , R. Barrile

The paper demonstrates that human immunocompetent Organs-on-Chips can predict safety liabilities of T-cell bispecific antibodies targeting tumor antigens.

bioRxiv · Feb 22, 2021Cancer Biology